Last reviewed 2026-04-23 · How we verify

Carboplatin AUC2

Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription.

Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription. Used for Ovarian cancer, Breast cancer, Lung cancer.

At a glance

Mechanism of action

Carboplatin is a platinum-based chemotherapy drug that works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.

Approved indications

• Ovarian cancer
• Breast cancer
• Lung cancer

Common side effects

• Myelosuppression
• Nausea and vomiting
• Neuropathy

Key clinical trials

• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
• A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC (PHASE2)
• Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer (PHASE2)
• PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer (PHASE2)
• Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009) (PHASE2)
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (PHASE2)
• Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC (PHASE3)
• A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.